Barely Significant

Excerpts

514,629 sentences

modestly significantp<0.051.0× alphaqualifiedgold
In the Cox-PH analysis, along with a focused MMS, the ages of the patients at the initial diagnosis and a binary measurement variable indicating the presence of somatic mutation on TP53 gene, which had a modestly significant (p<0.05) effect on the patient survival as shown in our preliminary analysis of the same data, were included as covariates.
highly significantp < 0.051.0× alphaqualifiedgold
SBP, DBP, PP and MAP, UPr were observed to be higher among the groups with nephroaphty and CKD/DKD with highly significant p-values (all p < 0.05).
borderline significantp=0.051.0× alphagold
Heterogeneity and sensitivity analysis There was borderline significant statistical heterogeneity between DM cohort studies in unadjusted risk (Tau 2 =0.042, Cochran’s Q=9.50, p=0.05, I 2 =62.3%), however there was significant heterogeneity when risk was adjusted (Tau 2 =0.070, Cochran’s Q=13.70, p=0.008, I 2 =80.2%).
nominally significantp < 0.051.0× alphagold
Longitudinal assessment of circulating levels of 29 immune biomarkers revealed that mean levels of nine molecules (IL-1β, IL-1RA, IFN-γ, eotaxin, MCP1, MDC, MIF, RANTES, and HGF) showed changes across the experimental time points that were nominally significant (p < 0.05, Table 1 ).
highly significantp < 0.051.0× alphaqualifiedgold
EASI and SCORAD scores were lower in all groups at 2 nd consultation ( p < 0.05); however, these were highly significant for group 3 ( p < 0.05); however, these were highly significant for group 3 ( p < 0.05); however, these were highly significant for group 3 ( p < 0.05); however, these were highly significant for group 3 ( Conclusion A reduction in severity following objective assessments of the AD was observed for all groups and was highly significant for patients offered a memory button and the corresponding app.
highly significantP < 0.051.0× alphaqualifiedgold
First, oral administration of the ethanolic extract of WGM in the diabetic group revealed a highly significant reduction ( P < 0.05; blood glucose levels by two-way ANOVA, followed by Tukey’s multiple comparison test) in blood glucose levels starting on the seventh day of treatment (234.50 ± 14.28 mg/dl) compared to the levels in the same group before treatment (day 0) (370.0 ± 4.81 mg/dl) as well as the levels in the diabetic group on the corresponding days (560.0 ± 13.06 and 371.50 ± 24.11 mg/dl, respectively).